Our Journey to Success

As a Stand Alone Company
Developing TWi's own generic and brand product for US market


Obtained Dimethyl Fumarate DR Capsule tentative approval and Fenofibric Acid DR Capsule final approval from US FDA.

Launched Cyclobenzaprine HCl ER Capsule and Diltiazem HCl ER Capsule in TWi's own label in US market since March and May.


Launched Bupropion HCl ER Tablet in TWi's own label in US market since October.

Obtained Oxcarbazepine ER Tablet tentative approval and Diltiazem HCl ER Capsule and Metoprolol Succinate ER Tablet final approvals from US FDA.


Divested the stake in Visum to other local partners with extensive supply chain resources in China to cope with policy changes and severer competition in China market. Visum remains one of TWi's major strategic partners as a CMO for US market.

Guanfacine ER Tablet, which was previously marketed by an external partner, has been successfully launched by TWi US under TWi label as of Aug'17. All the products developed by TWi, since then, are marketed via a well-established sales platform by TWi's fully owned subsidiary, TWi Pharmaceuticals USA, Inc.

Acquired the equity of Synpac-Kingdom Pharmaceutical Co., Ltd. to accelerate the portfolio expansion into ophthalmic products for the US market.


Visum completed audit by FDA, and became a qualified cGMP plant

TWi Biotechnology, Inc., TWi's 73%-owned subsidiary, began trading on the Emergin Market Board, stock ticker: 6610


Launched 2 products in TWi's own label in US market in March

Increased holding stake in Visum to 66%

Obtained Guanfacine ER Tablet final approval from US FDA and launched the product in US

Launched Megace ES in TWi's own label in US market in July


Obtained final approval of 3 ANDAs from FDA

Established US commercial operations and UK supply chain

Acquired 53% stake in Visum Pharmaceutical Co., China


Publicly listed on Taipei Exchange, stock ticker : 4180

Acquired U-Liang Pharmaceutical, Co.

Selected as "Key Counseling Mittelstand Target" by Taiwan's Industrial Development Bureau, Ministry of Economic Affairs


Began trading on the Emergin Market Board. Stock ticker: 4180

Received approval for stock public issuance

Completed share transfer with TWi Holding to allow the TWi Holdings' shareholders to directly own of TWi Pharmaceuticals' share

Chungli Plant completes PIC/C audit by FDA


Chungli Plant Passed Teva Global Quality System Audit

Completed acquisition of TWi Biotechnology, Inc. as 100% fully-owned subsidiary


Spun out the new drug development division as TWi Biotechnology, Inc. for the development of new drug

Complete corporate restructuring in which TWi Holdings had been separated from Anchen Inc. and become the parent company of TWi Pharmaceuticals, Inc.

As Anchen Inc. Subsidiary
Laying foundation for development of High Barrier Generics


Chungli plant OEM anti-epileptic drugs for Anchen and began exporting to USA‏‏


Chungli plant passed US FDA Pre-Approval Inspection


Completed acquisition of Empax Pharma and changed company name to TWi Pharmaceuticals, Inc.

Founding Period


Acquired Parke-Davis' production facility in Chungli‏


Anchen Inc. established Taiwan subsidiary, TWi Pharmaceuticals, Ltd.